Pharmaceutical markets in Japan and the United States

William S. Comanor ()
Additional contact information
William S. Comanor: Fielding School of Public Health, University of California

International Journal of Economic Policy Studies, 2022, vol. 16, issue 2, No 1, 355-370

Abstract: Abstract Although the United States and Japan are the two largest markets for branded pharmaceuticals, their structures and market performance are quite different. Like its European counterparts, a Japanese government ministry sets the prices paid to national and international drug companies. In contrast, US prices are set largely through negotiations between private health insurers and drug companies. Related to these different structures are quite different results. In particular, for pharmaceuticals sold in both countries, US prices are about twice what they are in Japan. Since many of the same companies sell pharmaceuticals in both countries, these differences require an explanation. A frequent one offered is that Japanese authorities exercise their inherent monopsony power to obtain the low prices, which private insurers in the United States are unable to impose. While correct on the surface, this explanation fails to confront deeper policy issue concerned with promoting public health. Because pharmaceutical research and development is a global public good, there are strong incentives for buyers to “free ride” on the outlays of others. Under those circumstances, global R&D outlays, based on country-specific incentives, would be set below optimal levels, and the supply price of substantial pharmaceutical innovation would not be covered. Because the US market is more than half the world total, its incentive structure is fundamentally different from that of Japan. Indeed, higher US drug prices, which drive worldwide incentives, are needed to promote current numbers of new pharmaceuticals introduced in both countries.

Keywords: Pharmaceutical innovation; Drug prices; Global public goods (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s42495-022-00085-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:ijoeps:v:16:y:2022:i:2:d:10.1007_s42495-022-00085-6

Ordering information: This journal article can be ordered from
https://www.springer ... policy/journal/42495

DOI: 10.1007/s42495-022-00085-6

Access Statistics for this article

International Journal of Economic Policy Studies is currently edited by Akira Maeda

More articles in International Journal of Economic Policy Studies from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().